EUVIMEDEUVIMED entdecken
Crossref

Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model

Neha Chauhan, Smita Jain, Paras Gupta, Jaya Dwivedi, Sarvesh Paliwal, Swapnil Sharma, Achal Mishra, Sudarshan Singh, Mini Rani Mary Beth, Manjula Arunraj

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-05 · 399 (8) · 11557-11579

DOI: 10.1007/s00210-026-05073-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 20.02.2026. Verfasst von Neha Chauhan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Glycogen Synthase Kinase 3 beta, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GSK-3β has been a key target in Alzheimer's disease (AD) research for over two decades. To identify novel GSK-3β inhibitors, 333 compounds from the National Cancer Institute (NCI) database were screened using a validated ligand-based pharmacophore model with four essential features (two hydrogen bond acceptors, one hydrophobic, and one aromatic ring). After tapering screening with refined boundaries, two top compounds (NSC 275 and NSC 3198) were identified. Molecular docking and simulation studies confirmed their strong binding affinity to GSK-3β. ELISA analysis revealed that their half maximal inhibitory concentration (IC50) values were comparable to the standard GSK-3β inhibitor, CHIR99021. Subsequent in-vivo studies assessed the efficacy of these chemical entities in tested mouse model. Acute toxicity studies demonstrated no observed adverse effect level (NOAEL). Whereas behavioral tests, using the Morris water maze, the tested compounds (5 mg/kg and 10 mg/kg) exhibited cognitive improvements comparable to those of the donepezil group (1 mg/kg), an approved AD treatment. Further analysis of oxidative stress, histopathology, and immune responses in the hippocampus (CA1) indicated that the NSC 275 and NSC 3198 reversed cognitive deficits similarly to the donepezil treated group. The results suggested that combination of in-silico, in-vitro, and in-vivo approaches demonstrates the potential of NSC 275 and NSC 3198 as promising GSK-3β inhibitors for AD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsAnimalsMolecular Docking SimulationMaleDisease Models, AnimalStreptozocinMiceComputer SimulationPharmacophore

Stichwörter der Autor:innen

Alzheimer’s diseaseGlycogen synthase kinase-3βImmunohistochemistryPharmacophore modelingWestern blotting

Substanzen

Glycogen Synthase Kinase 3 betaStreptozocinProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.
  • School of Pharmacy & Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, 425405, India.
  • Department of Pharmacognosy, United Institute of Pharmacy, Prayagraj, Uttar Pradesh, 211010, India.
  • Department of Chemistry, Banasthali Vidyapith, Tonk, 302022, Rajasthan, India.
  • Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India. achal.mishra03@gmail.com.
  • Office of Research Administration, Chiang Mai University, Chiang Mai, 50200, Thailand. sudarshan.s@cmu.ac.th.

Zitieren

APA

Chauhan, N., Jain, S., Gupta, P., Dwivedi, J., Paliwal, S., Sharma, S., Mishra, A., Singh, S., Beth, M. R. M., & Arunraj, M. (2026). Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(8), 11557-11579. https://doi.org/10.1007/s00210-026-05073-7

Vancouver

Chauhan N, Jain S, Gupta P, Dwivedi J, Paliwal S, Sharma S, et al. Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(8):11557-11579. doi:10.1007/s00210-026-05073-7

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Neha and Jain, Smita and Gupta, Paras and Dwivedi, Jaya and Paliwal, Sarvesh and Sharma, Swapnil and Mishra, Achal and Singh, Sudarshan and Beth, Mini Rani Mary and Arunraj, Manjula},
  title = {Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {8},
  pages = {11557--11579},
  doi = {10.1007/s00210-026-05073-7}
}
Kostenlos starten →